Analyst Research Report Snapshot

Title:

BAVARIAN NORDIC - EXPANDING THE BIODEFENCE BUSINESS

Price:

$10.00

Provider:

Edison Investment Research

Date:

26 Feb 2014

Pages:

6

Type:

AcrobatPDF

Companies referenced:

BAVA.CO

Available for Immediate Download
Summary:

Bavarian Nordic has been awarded a new US government biodefence contract for the development of infectious disease vaccines based on its MVA-BN platform. The $0.5m contract from the Defense Threat Reduction Agency (DTRA), part of the US Department of Defense, will fund the design, development and testing of vaccines against two bacterial pathogens, Burkholderia pseudomallei and Burkholderia mallei. Phase III prostate cancer vaccine Prostvac remains the key value driver for Bavarian Nordic; however, this contract win highlights its expertise in developing infectious disease vaccines and the strength of its MVA-BN platform. It also broadens the R&D pipeline and brings the value of US government biodefence contracts awarded to date to over $1.02bn.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.